Table 1 Patient characteristics at baseline, Full Analysis Set
Monotherapy Study | Combination Therapy Study | ||||
|---|---|---|---|---|---|
Dulaglutide 0.75 mg (N = 280) | Liraglutide 0.9 mg (N = 137) | Placebo (N = 70) | Dulaglutide 0.75 mg (N = 181) | Insulin Glargine (N = 180) | |
Females, n (%) | 52 (19%) | 24 (18%) | 15 (21%) | 56 (31%) | 47 (26%) |
Age (yrs), mean (SD) | 57.2 (9.6) | 57.9 (10.4) | 57.7 (8.3) | 57.5 (10.5) | 56.1 (11.3) |
Weight (kg), mean (SD) | 71.3 (12.5) | 70.2 (12.5) | 69.3 (11.6) | 70.9 (13.7) | 71.1 (13.8) |
BMI (kg/m2), mean (SD) | 25.6 (3.6) | 25.5 (3.5) | 25.2 (3.2) | 26.1 (3.6) | 25.9 (3.9) |
Diabetes duration (yrs), mean (SD) | 6.8 (5.6) | 6.3 (6.0) | 6.3 (5.1) | 8.9 (6.7) | 8.8 (6.1) |
HbA1c (%), mean (SD) | 8.2 (0.8) | 8.1 (0.9) | 8.2 (0.8) | 8.1 (0.8) | 8.0 (0.9) |
Receiving OHA at screening, n (%) | 94 (34%) | 48 (35%) | 22 (31%) | 181 (100%) | 180 (100%) |
OHA-naive, n (%) | 186 (66%) | 89 (65%) | 48 (69%) | 0 (0%) | 0 (0%) |
Concomitant OHA at baseline, n (%) | |||||
Sulfonylureas only | NA | NA | NA | 34 (19%) | 33 (18%) |
Biguanides only | NA | NA | NA | 64 (35%) | 66 (37%) |
Sulfonylureas and biguanides | NA | NA | NA | 83 (46%) | 81 (45%) |
EQ-5D-5L Japan Index, mean (SD) | 0.97 (0.06) | 0.97 (0.06) | 0.96 (0.08) | NA | NA |
EQ-5D VAS, mean (SD) | 82.6 (12.7) | 81.0 (11.4) | 79.3 (14.2) | NA | NA |